Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study

Panminerva Medica

Volumn 53, Issue 3 SUPPLEMENT, 2011, Pages 43-49

  Appendino, G ^a   Belcaro, G ^b   Cornelli, U ^c   Luzzi, R ^b   Togni, S ^d   Dugall, M ^b   Cesarone, M R ^b   Feragalli I, B ^b   Ippolito, E ^b   Errichi, B M ^b   Pellegrini, L ^b   Ledda, A ^b   Ricci, A ^b   Bavera, P ^b   Hosoi, M ^b   Stuard, S ^b   Corsi, M ^b   Errichi, S ^b   Gizzi, G ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c CorCon SrL ^*  (Italy)

^d INDENA S P A   (Italy)

Author keywords

Curcumin; Diabetes mellitus microcirculation; Diabetic angiopathies; Edema.; Laser Doppler flowmetry

Indexed keywords

CURCUMIN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG EFFECT; EDEMA; FEMALE; FOOT; HUMAN; MALE; MICROCIRCULATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYTOTHERAPY; PILOT STUDY;

AGED; CURCUMIN; DIABETIC ANGIOPATHIES; EDEMA; FEMALE; FOOT; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; PHYTOTHERAPY; PILOT PROJECTS;

EID: 84859470499     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Chertow B. Advances in diabetes for the millennium: Vitamins and oxidant stress in diabetes and its complications. Med Gen Med 2004; 6: 4.
2. Pergola PE, Krauth M, Hugg JW, Ferugson DA, Ruiz S, Meyer CJ et al. Effects of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011; 33: 469-76.
3. Honda T, Rounds BAV, Bore L, Finlay HJ, Favaloro FG, Suh N et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem 2000; 43: 4233-46.
4. [No authors listed]. Trial to determine the effects of bardoxolone methyl on eGFR in patients with type 2 diabetes and chronic kidney disease, [cited 2011 September 8]. Available at: http://clinicaltrials. gov/ct2/show/ NCT00811889?term=bardoxolone&rank= 1
5. Cesarone MR, Belcaro G, Rohdewald P. Improvement of diabetic microangiopathy with Pycnogenol: A prospective, controlled study. Angiology 2006;57:431-6. (Pubitemid 44449041)
6. Usharani P, Mateen AA, Naidu MUR, Raju YSN, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo controlled, 8-week study. Drugs R D 2008; 9: 243-50. (Pubitemid 351920123)
7. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 2003;371:887-95. (Pubitemid 36578887)
8. Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S. Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition 2009; 25: 964-72.
9. Sharma S, Kulkami SK, Agrewala JN, Chopra K. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 2006; 536: 256-61.
10. Kowluru RA, Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr Metab (Lond) 2007; 4: 8.
11. Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol 2007;576:34-42. (Pubitemid 47588254)
12. Aggawal BB, Harikumar KB. Potential therapeutical effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41: 40-59.
13. Best L, Elliott AC, Brown PD. Curcumin induces electrical activity in rat pancreatic beta-cells by activating the volume-regulated anion channel. Biochem Pharmacol 2007;73:1768-75. (Pubitemid 46601410)
14. Belcaro G, Cesarone MR, Errichi BM, Ricci A, Dugall M, Pellegrini L et al. Venous and diabetic ulcerations: Management with topical multivalent silver oxide ointment. Panminerva Med 2010; 52 ( 2 Suppl 1): 37-42.
15. Belcaro G, Nicolaides AN, Volteas N, Leon M. Skin flow: The venoarteriolar response and capillary filtration in diabetics. A 3-year follow-up. Angiology 1992; 43: 490-5.
16. Corsi M, Lacerna F, Borzone A, Belcaro G. Macro- and microcirculation study in diabetic patients]. Minerva Cardioangiol 1996; 44: 535-7.
17. Belcaro G, Laurora G, Cesarone MR, De Sanctis MT, Incandela L. Microcirculation in high perfusion microangiopathy. J Cardiovasc Surg (Torino) 1995; 36: 393-8.
18. Belcaro G, Cesarone MR, Ledda A, Cacchio M, Ruffini I, Ricci A et al. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(beta-hydroxyethyl)- rutosides: a prospective comparative clinical registry. Angiology 2008;59 (Suppl 1): 14S-20S. (Pubitemid 351253078)
19. Cesarone MR, Belcaro G, Grossi MG. O-(beta-hydroxyethyl)-ruto-sides (Paroven; Venoruton): new studies, improved safety, and novel cardiovascular applications. Angiology 2008; 59(Suppl 1):5S-6S. (Pubitemid 351253079)
20. Belcaro G, Rosaria Cesarone M, Ledda A, Cacchio M, Ruffini I, Ricci A et al. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology 2008;59(Suppl 1):7S-13S. (Pubitemid 351253077)
21. Cesarone MR, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G et al. Improvement of diabetic microangiopathy with pycnogenol: A prospective, controlled study. Angiology 2006; 57: 431-6. (Pubitemid 44449041)
22. Belcaro G, Cesarone MR, Errichi BM, Ledda A, Di Renzo A, Stuard S et al. Diabetic ulcers: microcirculatory improvement and faster healing with Pycnogenol. Clin Appl Thromb Hemost 2006; 12: 318-23. (Pubitemid 44400843)
23. Vinciguerra G, Belcaro G, Cesarone MR, Rohdewald P, Stuard S, Ricci A et al. Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology 2006; 57:331-9. (Pubitemid 44438553)
24. Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A et al. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther 2009; 25: 537-40.
25. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 2011; 74: 664-9.
26. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG et al. Product-evaluation registry of Meriva® a curcumin-phosphatidylcholine complex for the complementary management of osteoarthritis. Panminerva Med 2010; 52( Suppl. 1): 55S-62S.
27. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Opthalmol 2010, 4, 41-6.
28. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG et al. Efficacy and safety of Meriva®a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 2010; 15: 337-44.
29. Incandela L, Cesarone MR, DeSanctis MT, Belcaro G, Dugall M, Acerbi G. Treatment of diabetic microangiopathy and edema with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, placebo-controlled, randomized study. J Cardiovasc Pharmacol Ther 2002;7(Suppl 1):S11-5. (Pubitemid 34408829)
30. DeSanctis MT, Cesarone MR, Incandela L, Belcaro G, Acerbi G. Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). J Cardiovasc Pharmacol Ther 2002;7(Suppl l):S3-6. (Pubitemid 34408827)
31. De Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Ricci A, Griffin M. Four-week treatment with Essaven gel in diabetic microangiopathy~a placebo-controlled, randomized study. Angiology 2001;52(Suppl 3):S49-55. (Pubitemid 33140437)
32. Cesarone MR, Incandela L, Belcaro G, De Sanctis MT, Ricci A, Griffin M. Two-week topical treatment with Essaven gel in patients with diabetic microangiopath. - a placebo-controlled, randomized study. Angiology 2001;52 (Suppl 3): S43-8. (Pubitemid 33140436)
33. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M. Microvascular alterations in diabetic microangiopathy: topical treatment with Essaven ge. - a placebo-controlled, randomized study. Angiology 2001; 52 (Suppl 3): S35-41. (Pubitemid 33140435)
34. Incandela L, Cesarone MR, Cacchio M, De Sanctis MT, Santavenere C, D'Auro MG et al. Total triterpenic fraction of centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. Angiology 2001; 52 ( Suppl 2): S9-13.
35. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Bavera P, Bucci M et al. Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella asiática: a clinical prospective randomized trial with a microcirculatory model. Angiology 2001; 52(Suppl 2):S49-54. (Pubitemid 32963564)
36. Cesarone MR, De Sanctis MT, Incandela L, Belcaro G, Griffin M, Cacchio M. Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). Angiology 2001;52 (Suppl 2):S3-7. (Pubitemid 32963556)
37. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Nargi E, Patricelli P et al. Treatment of diabetic microangiopathy and edema with total triterpenic fraction of Centella asiática: a prospective, placebo-controlled randomized study. Angiology 2001;52 (Suppl 2):S27-31. (Pubitemid 32963560)
38. Belcaro G, Laurora G, Cesarone MR, De Sanctis MT, Incandela L. Microcirculatory effects of elastic stockings in diabetic microangiopathy: A 24-week study. J Cardiovasc Surg (Torino) 1993; 34: 479-82.
39. Belcaro G, Laurora G, Cesarone MR, De Sanctis MT, Renton S, Chong LC. Evaluation of arteriosclerosis progression with ultrasonic biopsy and intima-media thickness measurements. Vasa 1993; 22: 15-21. (Pubitemid 23107421)
40. Belcaro G, Laurora G, Cesarone MR, Pomante P. Elastic stockings in diabetic microangiopathy. Long-term clinical and microcirculatory evaluation. Vasa 1992; 21: 193-7.
41. Cesarone MR, Laurora G, Ricci A, Belcaro G, Pomante P, Candiani C et al. Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study). Vasa 1992; 21: 76-80.
42. Belcaro G, Nicolaides AN. The venoarteriolar response in diabetics. Angiology 1991; 42: 827-35.
43. Cesarone MR, Laurora G, De Sanctis MT, Ricci A, Pomante P, Belcaro G. Vascular reactivity related to postural changes in diabetics. Minerva Cardioangiol 1991; 39: 285-90.
44. Belcaro G, Christopoulos A, Nicolaides AN. Diabetic microangiopathy treated with elastic compression-a microcirculatory evaluation using laser-Doppler flowmetry, transcutaneous PO2/PC02 and capillary permeability measurements. Vasa 1990; 19: 247-51.
45. Belcaro G, Marelli C, Pomante P, Laurora G, Cesarone MR, Ricci A et al. Fibrinolytic enhancement in diabetic microangiopathy with defibrotide. Angiology 1992; 43: 793-800.
46. Stuard S, Belcaro G, Cesarone MR, Ricci A, Dugall M, Cornelli U et al. Kidney function in metabolic syndrome may be improved with Pycnogenol® Panminerva Med 2010; 52( 2 Suppl l): 27-32.
47. Cesarone MR, Belcaro G, Stuard S, Schönlau F, Di Renzo A, Grossi MG et al. Kidney flow and function in hypertension: Protective effects of pycnogenol in hypertensive participants-a controlled study. J Cardiovasc Pharmacol Ther 2010; 15: 41-6.
48. Belcaro G, Barsotti A, Nicolaides AN. "Ultrasonic biopsy. - A non-invasive screening technique to evaluate the cardiovascular risk and to follow up the progression and the regression of arteriosclerosis. Vasa 1991; 20: 40-50.
49. Steigerwalt RD Jr, Belcaro G, Cesarone MR, Laurora G, De Sanctis M, Incandela L et al. Doppler ultrasonography of the central retinal artery in patients with diabetes and vascular disease treated with topical timolol. Eye (Lond) 1995; 9 ( Pt4): 495-501.